Nuplazid 34 MG capsule 30S
Ended Awarded Last action
- Contract number
- SPE2DR26FQWL7
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $11,771
Award facts
- Contract value 100% obligated
- $11,771.46 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Nuplazid (pimavanserin) 34 mg capsules in quantities of 30 units. This firm fixed-price delivery order, valued at $11,771.46, was awarded on January 20, 2026, with an ultimate completion date of February 10, 2026. The award carries no set-aside designation, indicating DMS Pharmaceutical Group competed successfully in an unrestricted procurement environment. Performance will be executed at the contractor's facility in Park Ridge, Illinois.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion government-wide acquisition strategy designed to supply the Department of Defense with pharmaceutical products and medical consumables. The PPV-G GEN V contract, awarded to DMS Pharmaceutical Group on November 13, 2025, with a $499.999 billion ceiling value and completion date of December 31, 2036, authorizes DLA to issue delivery orders for branded and generic prescription medications, biologics, vaccines, and medical supplies to support military healthcare facilities worldwide. The contractor has demonstrated substantial federal pharmaceutical supply chain performance through numerous prior delivery orders across diverse therapeutic categories.
Quick answers
Who was awarded contract SPE2DR26FQWL7?
SPE2DR26FQWL7 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 20, 2026.
How much is contract SPE2DR26FQWL7 worth?
The government has obligated $11,771 on SPE2DR26FQWL7.
Is contract SPE2DR26FQWL7 an order under another contract?
Yes. SPE2DR26FQWL7 is a delivery order under SPE2DR25D9353, an indefinite delivery contract.
Was contract SPE2DR26FQWL7 competed?
The extent of competition for SPE2DR26FQWL7 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award